Literature DB >> 2096600

Interferon levels in human pulmonary tumors are lower than plasma levels.

V Bocci1, F Carraro, A Naldini, E Borrelli, G Biagi, G Gotti, P P Giomarelli.   

Abstract

It is uncertain whether interferon levels in the interstitial fluid of tumors are equivalent to interferon plasma levels and we have investigated this problem in human pulmonary tumors by infusing human recombinant interferon alpha A and natural interferon Beta for about three hours before surgery. By determining the hematocrit and hemoglobin content it was possible to calculate interferon values (International Units/g wet tissue) present in the interstitial fluid of tumor and lung samples, simultaneously. In 14 patients (epidermoids, n = 9 and adenocarcinomas, n = 5) interferon levels in tumor and "normal" lung expressed as percentages of interferon plasma levels were: 9.5 +/- 3.9 and 29.8 +/- 6.9 for recombinant interferon alpha A and 3.1 +/- 0.4 and 10.1 +/- 2.4 for natural interferon Beta, respectively. Differences for both interferons are statistically significant (p less than 0.05). To our knowledge these are the first data indicating that interferon levels in pulmonary tumor interstitial fluid are markedly lower than those in normal lung although they do not clarify the main factor responsible for the decrease, they explain at least in part the negligible therapeutic activity of interferons in these tumors and emphasize the need for new approaches for improving the therapeutic index of interferons.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2096600

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  3 in total

Review 1.  Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer.

Authors:  Qi Bao; Yue Zhao; Hanno Niess; Claudius Conrad; Bettina Schwarz; Karl-Walter Jauch; Ralf Huss; Peter J Nelson; Christiane J Bruns
Journal:  Stem Cells Dev       Date:  2012-06-26       Impact factor: 3.272

2.  Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia.

Authors:  W E Aulitzky; C Peschel; D Desprès; J Aman; P Trautman; H Tilg; G Rudolf; H Hüttmann; J Obermeier; M Herold
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

Review 3.  Genetically modified mesenchymal stromal cells in cancer therapy.

Authors:  Elizabeth K Sage; Ricky M Thakrar; Sam M Janes
Journal:  Cytotherapy       Date:  2016-11       Impact factor: 5.414

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.